Floatz logo

Yttrium Y 90 Basiliximab

Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma

City of Hope Medical Centermonoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

62 Active assets in the Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Yttrium Y 90 Basiliximab is also rated in:

Hodgkins lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
mature T-cell and NK-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
44 / 100
View asset →
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →